SOUTH SAN FRANCISCO, Calif.,
Dec. 5, 2018 /PRNewswire/
-- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced
that Dean Schorno, the company's
executive vice president and chief financial officer, is scheduled
to present a company overview at the BMO Capital Markets 2018
Prescriptions for Success Healthcare Conference on Wednesday, December 12, 2018 at 2:20pm EST.
To access the live webcast of the presentation or the subsequent
archived recording, log on to www.rigel.com. Please connect to
Rigel's website several minutes prior to the start of the live
webcast to ensure adequate time for any software download that may
be necessary.
About Rigel (www.rigel.com)
Rigel Pharmaceuticals,
Inc., is a biotechnology company dedicated to discovering,
developing and providing novel small molecule drugs that
significantly improve the lives of patients with immune and
hematologic disorders, cancer and rare diseases. Rigel's pioneering
research focuses on signaling pathways that are critical to disease
mechanisms. The company's first FDA approved product is TAVALISSE™
(fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase
(SYK) inhibitor, for the treatment of adult patients with chronic
immune thrombocytopenia who have had an insufficient response to a
previous treatment. Rigel's clinical programs include an upcoming
Phase 3 study of fostamatinib1 in autoimmune hemolytic
anemia and an ongoing Phase 1 study of R8351, a
proprietary molecule from its interleukin receptor associated
kinase (IRAK) program. In addition, Rigel has product candidates in
development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris
Therapeutics.
1 The product for this use or indication is
investigational and has not been proven safe or effective by any
regulatory authority.
Please see www.TAVALISSE.com for full Prescribing
Information.
Contact: David Burke
Phone: 650.624.1232
Email: dburke@rigel.com
Media Contact: Jessica Daitch
Phone: 917.816.6712
Email: jessica.daitch@syneoshealth.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/rigel-to-present-at-the-bmo-capital-markets-2018-prescriptions-for-success-healthcare-conference-in-new-york-city-300760320.html
SOURCE Rigel Pharmaceuticals, Inc.